|1.||Rider, Lisa G: 26 articles (12/2014 - 03/2003)|
|2.||Reed, Ann M: 19 articles (12/2015 - 01/2002)|
|3.||Miller, Frederick W: 19 articles (09/2014 - 03/2003)|
|4.||Feldman, Brian M: 18 articles (04/2014 - 11/2002)|
|5.||Pachman, Lauren M: 18 articles (10/2013 - 04/2002)|
|6.||Huber, Adam M: 14 articles (05/2014 - 03/2008)|
|7.||Wedderburn, Lucy R: 13 articles (09/2015 - 06/2004)|
|8.||Kuwana, Masataka: 9 articles (05/2015 - 07/2009)|
|9.||Sato, Shinji: 8 articles (12/2015 - 07/2009)|
|10.||Ravelli, Angelo: 8 articles (05/2015 - 12/2003)|
05/01/2014 - "This therapy may have a role in improving calcinosis, even if more studies are necessary to determine the safety and efficacy of this treatment in juvenile dermatomyositis-related calcinosis. "
10/01/2002 - "Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis."
08/01/2012 - "No risk factors for calcinosis were identified in this study, although that complication was found in half of the patients with juvenile dermatomyositis studied."
08/01/2012 - "High frequency of calcinosis in juvenile dermatomyositis: a risk factor study."
01/01/2004 - "The objective of this study was to begin to relate the microstructure of calcinosis samples to clinical and laboratory characteristics of the juvenile dermatomyositis (JDM) patients. "
|2.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
10/01/2014 - "In this article we review evidence from recent trials of the use of biologic drugs in the treatment of systemic JIA, juvenile dermatomyositis and juvenile systemic lupus erythematosus. "
07/01/2014 - "In this article we review evidence from recent trials of the use of biologic drugs in the treatment of systemic JIA, juvenile dermatomyositis and juvenile systemic lupus erythematosus. "
03/02/2000 - "The aim of our study was to describe typical magnetic resonance imaging findings and to investigate the usefulness of this method in detecting active muscle disease in juvenile dermatomyositis and juvenile systemic lupus erythematosus patients. "
09/01/2013 - "Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis."
09/01/2008 - "Children and adolescents with juvenile dermatomyositis and systemic lupus erythematosus also exhibit impaired exercise capacity. "
|3.||Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
02/01/2009 - "MRI in juvenile idiopathic arthritis and juvenile dermatomyositis."
07/01/1998 - "Children with juvenile chronic arthritis comprised 28.8% and juvenile dermatomyositis 10%. "
08/01/1997 - "New-onset juvenile dermatomyositis: comparisons with a healthy cohort and children with juvenile rheumatoid arthritis."
01/01/2013 - "To date, core sets of response variables are defined for juvenile idiopathic arthritis, juvenile systemic lupus erythematosus, and juvenile dermatomyositis, as well as definitions for improvement in response to therapy. "
08/01/2008 - "The PRINTO and PRCSG networks have standardized the evaluation of response to therapy in juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus, and juvenile dermatomyositis, drafted clinical remission criteria in JIA, and provided cross-cultural adapted and validated quality of life instruments including the Childhood Health Assessment Questionnaire and the Child Health Questionnaire into 32 different languages. "
|4.||Interstitial Lung Diseases (Interstitial Lung Disease)
01/01/2013 - "Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases."
04/01/2015 - "The aim of this study is to evaluate the factors associated to 1-year mortality in clinically amyopathic dermatomyositis (CADM) patients with acute interstitial lung disease (ILD). "
05/01/2013 - "To study the clinical features and associated risk factors of interstitial lung disease (ILD) in clinically amyopathic dermatomyositis (CADM) in Chinese patients. "
10/01/2007 - "The aim of the study was to investigate the characteristics of adult clinically amyopathic dermatomyositis (CADM) with rapid progressive interstitial lung disease (ILD). "
11/01/2006 - "The aim of the present study was to clarify the clinical characteristics and prognosis of patients with interstitial lung disease (ILD) associated with amyopathic dermatomyositis (ILD-ADM). "
|5.||Myositis (Idiopathic Inflammatory Myopathies)
03/01/2003 - "As part of this ongoing international effort, members of this group met in November 2001 at a work-shop entitled "Defining Clinical Improvement in Adult and Juvenile Myositis." A goal of the work-shop was to review current data on the validity and responsiveness of the recently published proposed preliminary core set measures for disease outcome assessment in clinical trials for myositis and to define the degree of change in each core set measure that is clinically meaningful. "
09/01/2014 - "Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool."
04/01/2011 - "The aim of this study was to define the standardized incidence ratio (SIR) of malignancy and the potential risk factors of concomitant malignancies in patients with inflammatory myopathies, including clinically amyopathic dermatomyositis (CADM). "
01/01/2011 - "A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies."
04/01/2003 - "To study the relationships of muscle strength and maximal oxygen consumption (VO(2peak)) with Childhood Health Assessment Questionnaire (CHAQ) score, Childhood Myositis Assessment Score (CMAS) and Child Health Questionnaire [physical summary (CHQ-PhS) and psychosocial summary (CHQ-PsS)] scores in juvenile dermatomyositis. "
|5.||Aluminum Hydroxide (Algeldrate)
|6.||Alendronate (Alendronate Sodium)
|10.||Adrenal Cortex Hormones (Corticosteroids)
|1.||Transplantation (Transplant Recipients)